Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C virus infection

Warfarin Anticoagulation for liver Fibrosis in patients Transplanted for hepatitis C virus infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12504151

Enrollment

Registered

2008-10-31

Start date

2007-07-01

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of liver fibrosis in patients who have received a liver transplant as a result of hepatitis C virus (HCV) infection Digestive System

Interventions

Warfarin (anticoagulation) for a duration of 2 years at a dose to maintain the international normalised ratio (INR) at 2 - 3. The warfarin will be taken orally on a daily basis. The control group will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hepatitis C virus (HCV) infection 2. Aged over 17 years, either sex 3. Liver transplant within previous 4 months 4. Informed consent

Exclusion criteria

Exclusion criteria: 1. Patients requiring anticoagulation for existing clinical indications 2. Standard contraindications to anticoagulation (active peptic ulcer disease, past history of haemorrhagic stroke, thrombocytopaenia (platelets count less than 90 x10^9/L) 3. Large oesophageal varices persisting post-transplant 4. Cerebrovascular abnormalities on pre-transplant computed tomography (CT) scan 5. Human immunodeficiency virus (HIV) antibody positive

Design outcomes

Primary

Measure	Time frame
Stage of liver fibrosis at end of treatment period (2 years)	—

Secondary

Measure	Time frame
1. Number of activated hepatic stellate cells per high power field on liver biopsy 2. Non-invasive measures of liver fibrosis	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026